Immuron fy23 sales increase 136% on fy22 sales

Highlights: australian fy23 sales of a$1.16 m (478% increase on fy22 sales) usa fy23 travelan® sales of a$643 k (28% increase on fy22 sales) global fy23 sales of a$1.80 m (136% increase on fy22 sales) melbourne, australia, july 05, 2023 (globe newswire) -- immuron limited (asx: imc; nasdaq: imrn), an australian based and globally integrated biopharmaceutical company is pleased to announce fy23 sales (unaudited net sales) results of its over-the-counter gastrointestinal and digestive health immune supplement travelan® and protectyn®. sales of travelan® and protectyn® increased by 136% in fy23 to aud $1.80 m, compared to aud $765 k in fy22.
IMRN Ratings Summary
IMRN Quant Ranking